{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117150","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.190822+00:00","generated_at":"2026-06-21T23:00:20.435895+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VYNE Q3 net loss $9.5M; VYN201 Phase 1a/b enrollment imminent; FMX114 strategy under review","bullets":["Q3 2022 net loss $9.5M vs $21.3M; operating loss $9.3M vs $14.3M year-over-year.","IND cleared for VYN201; first patient expected in Phase 1a/b vitiligo trial Nov. 2022 with topline data H1 2023.","FMX114 Phase 2a missed primary endpoint at week 4 but statistically superior at weeks 1-3; evaluating strategy for moderate-to-severe AD.","VYN202 oral BETi program progressing with Tay Therapeutics toward lead candidate selection.","Corporate presentation posted; cash position not separately disclosed in released results."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117150","json":"https://secwatch.observer/filing/0001104659-22-117150.json","markdown":"https://secwatch.observer/filing/0001104659-22-117150.md","text":"https://secwatch.observer/filing/0001104659-22-117150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922117150/0001104659-22-117150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922117150/tm2230087d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:00:20.435895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8987af02621a4c4e825987f77c7fa705671f954","claim":"VYNE Therapeutics Inc. reported three and nine months ended September 30, 2022 results: net income Net loss (GAAP) $ (9,459 ) $ (21,285 ) $ (13,265 ) $ (61,759 ).","evidence_excerpt":"VYNE Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922117150/0001104659-22-117150-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Net income","value":"Net loss (GAAP) $ (9,459 ) $ (21,285 ) $ (13,265 ) $ (61,759 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}